Vericel Corp
VCEL
Company Profile
Business description
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Contact
64 Sidney Street
CambridgeMA02139
USAT: +1 617 588-5555
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
357
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,203.90 | 28.80 | 0.35% |
| CAC 40 | 7,610.24 | 73.98 | 0.98% |
| DAX 40 | 22,395.45 | 153.00 | 0.69% |
| Dow JONES (US) | 40,284.96 | 171.46 | 0.43% |
| FTSE 100 | 8,446.30 | 31.05 | 0.37% |
| HKSE | 21,971.96 | 8.78 | -0.04% |
| NASDAQ | 17,350.40 | 32.54 | -0.19% |
| Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
| NZX 50 Index | 12,098.89 | 81.05 | 0.67% |
| S&P 500 | 5,530.70 | 5.49 | 0.10% |
| S&P/ASX 200 | 7,997.10 | 28.90 | 0.36% |
| SSE Composite Index | 3,288.41 | 6.65 | -0.20% |